In this episode of SNL, we sat down with Marcus Mounir Hanana (https://www.linkedin.com/in/mmhanana/), CEO of (https://www.pantherls.com/)Panther Life Sciences (https://www.pantherls.com/). Panther is developing SmartPatchâ„¢, a shelf-stable micron...
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
[upbeat music] When you build a physical product, I think the right advice is very quickly to do so with the first product and learn along the way so that you, you know, touch the whole supply chain, the whole value chain. Mm. It is just super easy to sit here and have, you know, hours of discussion between you and I around how we think the product should look like and make nice graphs and, you know, have a couple of scientists who figure out what could be the next molecule, and we're gonna be very, very happy people. But when you start to really produce more than, like, 10 a day, 100 a day, 1,000 a day, you're like, "Oh, wow, this is hard. This is really hard." And I think that's what we're trying to do.
We're trying really to earn the right to do more via doing the hard things first. [upbeat music] Hey, everyone. In this episode of SNL, we sat down with Markus Mounir-Hanana, CEO of Panther Life Sciences. Panther is developing SmartPatch, a shelf-stable microneedle patch whose dissolving needles deliver treatments through the skin, starting with premium cosmetics and expanding toward therapeutic applications. Before joining Panther in 2026, Mounir spent 25 years at Procter & Gamble and Amazon. At P&G, he held finance leadership roles across innovation, supply chain, and commercial operations in Europe and Africa.
At Amazon, he served since 2015 in several different roles, most recently as divisional CFO for US Home and Lifestyle before becoming CFO of Amazon Business, which grew under his leadership from about $25 billion to $60 billion in four years. Here are a few topics we explored in this conversation. First, how do you adapt proven big company operating habits within a startup? Second, what does launching a first product teach a company that years of R&D can't? Third, how does a technology with many possible markets earn the right to pursue bigger applications? And last, best practices for using investors and advisors as an extension of a small team.
Before we dive into today's episode, a quick heads-up that the full MedSider interview archive has officially moved over to my personal platform at scottnelsonlive.com. Our popular courses are now available there too, and they're free. Speaking of courses, if you're a founder or CEO preparing to raise capital, you should check out the fundraising cohort. This four-week live workshop combines small group sessions with real-time feedback to help you sharpen your investor story, build a targeted investor pipeline, and run a focused fundraising sprint instead of a never-ending slog. Over the month, you'll walk away with an investor-ready narrative and deck, outreach scripts that actually get responses, a refreshed LinkedIn profile, a simple content plan that keeps you on investors' radar, and a repeatable system for running your raise.
You can join the waitlist at scottnelsonlive.com/courses. Again, that's scottnelsonlive.com/courses. All right, let's get to the interview. [upbeat music] All right, Mounir. Welcome to the program. Appreciate you coming on. Yeah, thank you for having me. Excited to be here. The folks listening don't get a chance-- Or maybe they'll see a, they'll see a video clip of, of your, of your great background, right? Which is, uh, filled with, with lots of books. And I'm hoping we can tap into some of these, these learnings, whether you pick them up in a, in one of your books, or whether it's, uh, it's been, uh, it's been sort of gleaned from your, um, your pretty vast experience at some pretty, some of the bigger companies in the world.
So with that said, I recorded a very abbreviated bio outside of this episode, but I always like to start there. Like, what's the, what's the one or two-minute kinda elevator pitch on your, your journey leading up to taking on the, the CEO reins at, uh, at Panther? Yeah. Look, I spent, uh, almost 25 years, you know, between actually two companies now with a lot of different, uh, subsidiaries in different places. But I was at P&G and at Amazon. I started work at P&G a-after university. Had a great time there, you know. Different continents, worked different businesses at different areas.
But I think the, the one thing which, you know, stuck with me, what I felt I really learned there was, you have an idea for a product, and you need to bring it to millions of people. And the idea is probably sometimes quicker than the execution because now suddenly you need to manufacture supply chain, you need to build a brand, you need to communicate, and that is a lot of work and, you know, a lot of detailed work. The operational execution just really counts. And, you know, one example, you know, comes to mind is we had a big factory in France, and we needed to build another one for all of Eastern Europe.
And then so we stood up a factory in the eastern part of Romania in the middle of nowhere. And that was actually a really, really cool experience. You know, to go there from a green field, there was nothing, and two years later, you had a line running, and there was a factory and people working in it, and you, you got product out. That I was-- would say was one of the, the, the most fulfilling experiences I had. Mm. 'Cause it's very tangible, right? Physical product is very tangible. And then at Amazon, I think, you know, it was a bit of a continuation because you also have to do with physical product. It, it is easy to-- Not easy, but it is easier to have a digital product and write software, and you can, especially once you've done it, easily distribute it. Mm-hmm. Your distribution is actually instant almost, right?
When you have to do something, you produce something, or you have to distribute something like Amazon, you know, there's the, the physical world is there, and the physical world is sometimes a bit against you, right? There's weather, there's like you- Mm. You have to take care of a lot of people. And so at Amazon, you know, it was at first when I started, it was a lot about, you know, learning how platforms work and flywheels work and understand how the internet monetizes. I thought that was super interesting. That was something I hadn't seen at P&G. And then my last four years, I served as a CFO for Amazon Business, which was super interesting.
It was, um, you know, selling B2B essentially to, uh, any enterprise or small company in the world, 12 countries in the world, and it was a great, great experience in the sense that we, we really scaled it from, from 25, 26 billion to 60 this year in like four years. Yeah. So that, that was, was very, very exciting, you know, when you have the ability and the resources to really go big. You have, I, I bet, some amazing, uh, amazing experiences that maybe we'll, we'll touch on a little bit throughout the course, but we probably don't have enough time to get to all of them. But yeah, I mean, the, the, the two most, you know, arguably no- most notable kind of, you know, even though you were CFO of Amazon Business per se, Amazon and P&G, like, two most notable consumer brands of, like, you know, the last, what, 50 to 100 years?
I mean, it's pretty, pretty, pretty wild experiences, for sure. Um, but you made the decision to take on the CEO role at, at Panther. We're recording this in Q4 of '26, but just a, just a few months ago, right? So you're going from massive, massive, you know, global scale sort of operations to a, a, a startup. So for those that aren't familiar with the company, maybe let's start with, with what, what are you doing at Panther? And then we'll maybe dive into kind of, like, what you, uh, why go to sort of the, the opposite end of the spectrum in terms of businesses, right? From, from huge- Right... company to, to small startup. You know, let me, let me, if you're okay, let me turn it around a bit because, you know, there, there is a bit of a very personal story why I wanted to go into more an entrepreneurial area. Mm-hmm.
So I studied mathematics, actually, back in Germany many, many years ago. You know, and then went into the business, and I always wanted to do an MBA, and I never did. Hmm. And, like, two years ago, I had this discussion with my wife, and she's like, "Don't you think it starts being a little bit weird now still doing an..." [laughs] You know, "You're getting a bit late," is what she told me. "You're getting old." [laughs] And so, uh, instead of that, I went actually to Stanford and did kind of a summer program, they call it SEP, which I thought was really amazing, and that really increased even my excitement or thirst for going for more entrepreneurial, smaller company.
Hmm. That's why I kind of at the end was, was open and looking, looking to do something more entrepreneurial. Now let's talk about Panther. The reason why I got really excited about Panther when I met the founder, Carlos Bola, is that it has two things. The one is it has really, really deep purpose, and I'll explain it in a second, in, in being able to, to change something for the better in the world. But the second piece is also there's not many businesses I've seen which really are able to be real platform businesses and have a self-reinforcing flywheel if you get it right. And Panther has both of them. Hmm.
So Panther has a unique technology which allows to deliver essentially any treatment anywhere in the world in a very simple way. It is also possible to build really a very broad platform from a consumer side, but also from a, from a partner and pharma side. Got it. And, uh, probably should dive into what that exactly means. Yeah, yeah. I mean, I'm looking at the website right now, which is, you know, pantherls.com, just as it sounds. We'll link to it in the full writeup for this particular episode, but pantherls.com. Give us a sense of, like, if I'm, if I'm a... If you're sharing your, your, your career journey to a group of high school students, right? Right. Like, what is, what is Panther?
Give me a, give me a high-level overview of what this, what this, what this is. You know, the way I always start is with the science behind it. So I start always to say, "Did you know there's about two billion people in the world which are untreated and about 4.6 billion which are undertreated largely because of how we deliver treatments?" Hmm. Which is today in a syringe or in a pill or... Right? In the US alone, the pharma industry loses about $35 billion every year because cold chains break down, which is because you need to put the vaccine, for example, into a fridge end to end. Hmm. Right?
And about 50% of global vaccines are actually discarded and thrown away. What, what was the percent again? 50%, 5-0. Wow. Wow, okay. You can check that on the internet. Yeah. Like, you have two billion people who are untreated, and 50% of the stuff we throw away. Sounds a bit, little bit like food, right? Hmm. We throw a lot away, and there's still a lot of people who don't have enough to eat. And what the amazing part of Panther is, the core of the company is what we call a, our smart patch, which essentially is a microneedle patch which is shelf-stable, but it doesn't have needles out of steel.
The needles are made out of formula. Hmm. So you put it on your skin, and it dissolves. Hmm. And you have it in your body. Now, that's the one part, is the technology, right? The second part which I think is super exciting on that, which I always ask people when they ask me what I'm doing and say, "What do you know about skin biology?" Hmm. And the answer of most people is, "Actually, not much." Now, the interesting thing is that, uh, we all know that the skin is probably one of the or the biggest organ in, in the human body. Hmm.
But, uh, what I also did not know is that the skin has amazing immunoactivation properties the rest of the body doesn't have. And, you know, it goes back actually to a gentleman called Jenner in 1796 who had the idea to take cowpox and cut it into a little boy's arm, and he didn't die. So that was the first time you had this scarification done. And then much, much later there was, you know, the Nobel Prize, Steinman, and he figured out that all these immune cells running around in your, in your skin.
Hmm. And so whilst I would love to say that we wanna get the Nobel Prize, uh, that's not what we do. What we do is not chasing Nobel Prize. We're commercializing existing skin biology, and that means essentially that pretty much any molecule, any treatment is much better ended up in your skin- Hmm... than in any other part of your body. The reason why you get today a vaccine with a, with a syringe is because, well, in the muscle you can get it because nobody's gonna kill you, right? Like, even if a monkey would give it to you, you don't die, right?
But actually, it's not a great place to put a vaccine, in your muscle. So, so this is... I mean, is, is the best way to kinda think about this for someone that, that's, that's new to Panther is a much better delivery vehicle for, it could be a vaccine, it could be... I mean, na- name your sort of probably therapeutic, right? A, a peptide, a- Right. Peptide, exosomes, could be anything. Anything. Wow, okay. Okay, and the unique thing about Panther is that, that... Or one of the unique things, I should say, is it dissolves, right? So there's no patch to rip off and dispose of. It's, it dissolves into your skin. Well, there's a patch. Yeah. So there's a patch, but the, the needles themselves are gone once they dissolve on the skin. Ah, okay. Interesting. Okay. So there's still a patch- With a backing.
The really exciting part of it is when you think about it, you know, there's only about 1% of a topical going through your skin. Hmm. 1%. All the rest you wash off. The problem is that your skin is actually a really good barrier. Hmm. It's supposed to be a really good barrier. That's the whole job of your skin- Hmm... is not letting anything in. But once you pass the first layer of the skin, the stratum corneum, you have access to really the interesting parts of your skin. And if you just take cosmetics as the most simple example, I'm sure you know all these creams with hyaluronic acid and collagen. [laughs] You know, collagen molecules are actually pretty big. They're proteins.
And they're, you know, 5,000 to 10,000 Dalton big, which is the molecular weight of the, of the item, right? Hmm. But the skin doesn't let anything through which is bigger than 500. So anything, whatever somebody tells you is in the cream- Hmm... it's not gonna make it through your skin. That's for sure. Mm-hmm. And so we have a technology which allows you to deliver these things, and this will be actually our first product, which will allow to deliver just to the, simply to the skin things like hyaluronic acid and collagen where it belong. Super interesting, yeah. So, so a much, much better, uh, delivery mechanism. So I mentioned we're recording this in, in, in Q4 of, of '26 here.
For someone listening after the fact, give us a sense for kind of where, where the company's at, at today. I mean, are you, are you still, um, k- clinical stage? Or are you, are you, uh, you know, planning on commercializing kind of the first application at a future date? Give us a sense for kind of where, where you're at today. Yeah, no, that's a great question. So, uh, we've completed early human studies, uh, on safety and, um, and tolerability, and we'll, uh, actually share that I think this or next week will be the press release coming out. Hmm. Uh, and we're in the middle actually of a 40 person efficacy study for the product, and so that's super exciting. We started, uh, to work on our capabilities to manufacture and building up the team, and by next summer we're, we're thinking about, you know, launching our first product. Okay, okay.
So 2- 2027 kind of first, uh, you know- Right... potentially first, uh, first big year of, uh, of, of commercial, early commercialization efforts. So super helpful overview. Um, let's, uh, let's spend the next 30 minutes or so kind of going back in time and learning a little bit more about kind of your experiences, right, at P&G, at Amazon, and kind of what you're bringing into, to, to Panther and kind of, um, some of the unique decisions that you have to, you, you are making and, and you have to make, you know, in the, in the, in the years ahead. So first question on the, on the, on the docket is kind of leaning into your, your previous experiences at, at P&G and Amazon. Like, you, you probably looked at a number of different opportunities, right? You could have.
I mean, CFO of Amazon Business, right? You could a- you coulda had your pick, but you chose Panther. So why did you decide to kind of go all in on Panther versus maybe, uh, you know, a few other, a few, few other opportunities? You touched on, on a couple reasons, but let's drill into that in a little bit more detail. Yeah. No, I think, you know, uh, it's, it's, it's, it's the right question because that's a question I've asking myself for- [laughs]... for a while. And I think it came down to a couple of pieces. The first one, I definitely want to do something I'm really excited about and which has purpose. And, uh, when I talked the first time with the founder, Carlos Bola, I had this, you know, picture in my head and it was, okay, so I can have s- this patch, which is shelf stable, and I can put it in a letter envelope and send it around the world.
Hmm. I thought that was an amazing purpose to work for. If we can get this done, and I'm actually very convinced we can get this done, that can be- make a big difference to a lot of people. It's number one. The second one, uh, Carlos is a serial entrepreneur, very, very successful, a, a great human being, and, uh, I, I felt there's a lot for me to learn. You know, Carlos did the IPO of Amazon. He did the IPO of Netflix. He was- Hmm... you know, helping, uh, Steve Jobs to sell NeXT to Apple at the time. Hmm. So he has tremendous amount of, of, you know, uh, learnings and experience, which I thought was, was very impressive.
And then last but not least, you know, um, of course, Panther. So Panther I thought was at a super interesting stage in terms of the capability, but then also it has a lot of depth in terms of IPs. The company has over 100 IPs already, so it's not just, you know, a very, very early startup with a couple of people trying to do something. There's a lot of scientific depth there. And the third one was about, hey, they're ready. They're, they're at the transition of commercializing something. They're not trying to keep this scientific for the next 10 years- Hmm...
which it will take you, for example, to qualify a vaccine, right? But they're going early. They start with, you know, simpler areas, and they're ready to start producing and learn all of that and go through that hard part. Hmm. Right? And I thought it was super interesting. And I felt also that with my experience from, from P&G and Amazon, I felt actually it was interesting, a, a sweet spot I haven't seen so before yet. So, you know, you need the consumer goods. You need the able- the ability to manufacture and going through all of that. But also the thought about how do we build really a, a broader platform of treatments, not just this one product? How do we think about- Hmm...
bringing partners in? I thought it was unique, and I felt somehow I fit in really well into that. Hmm. Yeah, it is, it is kind of, kind of a, a unique blend of, uh, uh, sort of opportunities, right, and skill sets that kind of align with what, uh, what you've done in the past but also what you can do in the future. So with that said, l- l- let's, let's, I wanna, like, t- you know, uh, double click into the, into your experiences at, at Amazon and P- P&G, right? P&G. 'Cause both companies are known for, like, their, their executional chops, right? Especially Amazon, right? I mean, I think we've all heard, heard the stories. You're pro- sounds like you're a big part of pr- big part of that execution over the past decade. So, so once you make the decision to kind of, "Okay, I'm, Panther's the company I wanna, I wanna lean into.
This is where I'm gonna k- go all in next," are there a couple, like, foundational things that, that you definitely want to bring over to, to Panther, right, that you gleaned from your experiences at both of those companies? Yeah, I think so. You know, I... And I, I probably can pick two or three, but the one is I think once you start working a company like P&G, you get, you know, so deeply focused on the consumer. And I remember our CEO at the time was AG Lafley, and he was an amazing CEO, and he was in, uh, every meeting and he would just say, like, consistently until nobody could, you know, was crazy about hearing it, is like, "The consumer is the boss."
And people would tell him in meetings, "This is how we wanna position the brand, and this is how we wanna sell it." And he's like- I don't care kind of what you think. What does the consumer think? Mm. What does he or she want? Do we really understand that? And it got so deeply ingrained in me that, you know, actually Amazon is similar in, in this customer focus on what is the right service, what is the right experience, and these two together are really powerful. And this kind of ends up in this working really backwards, right? And say, "How do I want the customer experience to be?"
And it feels sometimes in this technology space, not just in MedTech, but generally you start with the technology. You're not working it backwards. Mm. And one of the tools, uh, we use at Amazon for that, and you might have heard of that, was writing PR FAQs. Mm-hmm. So press releases and FAQs. And essentially you're supposed to write the press release of a product you have not built yet. Mm. That's how you go to a senior leader and say, "I wanna put resources on this." And it's hard because you sit down and then you start writing and you're like, "What do I actually want that user saying about the product?" Mm.
Not what do I as a tech person want to write about, how cool it is and what features it has. No, what, what are these people saying how it makes their life better, easier, faster? I think that's something I'm really trying to bring in the, into Panther in a very strong way. You know, when people have opinions around, we need to do A, B, or C. And it's like, are you thinking that? Mm-hmm. Do we think that's the best way to build it, or is that what we think consumers need and want? Hmm. And then linked to that, you know, is, is really the writing piece. I'm not a huge fan of PowerPoint presentations.
[laughs] They have their place, you know, in some simple updates, but I want my team to write. Hmm. Writing forces you to articulate and bring your thoughts together, and I've seen it over and over and over again. You know, PowerPoint is very forgiving. You make, like, two little snippet words and, like, people make up the rest. [laughs] But it's not about that. You know, on really important things, it's not about making up the rest, it's about that individual, that leader writing down exactly how they think about it strategically, but also in the detail of the execution.
The interesting part is it does take a bit of time to do so, but it's also true that you save a lot of time down the road because you have much less misunderstanding, significantly less iterations, and people understand faster, better what the problems are. Hmm. Yeah. Those two stories, two of which I, I think I, I, I... When people hear of, like, Amazon kind of, uh, contrarian kind of, um, sort of systems or processes, right? It's those two that come up the most, right? The, this kind of- Right... PR as, as a way of kind of disseminating, uh, or championing ideas internally, and then, and then the lack of Power- Those, those are true then.
Like, that was kinda commonplace inside- Oh, yeah, they are true. Yeah. And you know, I tell... We would go to Andy and, uh, you know, prepare our, our, what we call our OP1, you know. Yeah. Uh, it would be a pretty long document. It would take about one and a half hours to read the document. Hmm. Oh, wow. And then we would have a two and a half hour discussion. Okay. So very, very, very deep. There would be no room for misunderstanding or, "That wasn't clear to me." And, you know, it takes a long time to write these docs and a lot of iteration. You know, you need to be also always careful to bring this idea to new places. I'm a big fan of adapting them in the right way. Mm-hmm. I would not ask my team now to write a 20-page document. That's wrong. That- Hmm.
Like, Panther's a startup, right? Hmm. So what I'm asking is to say, write a one-page. Hmm. Or perhaps two. That's okay. Yeah. But it can't be, like, two slides with three words on a PowerPoint. Right. And so I think finding the middle ground when you go from one place to the other, what have been good ideas, what worked well, yes, sure, but you need to adapt them. It's not right just to bring the same thing and then stubbornly trying to push it through. Yeah. No. You're dead right though. Like, anyone who's spent time kind of in, in the world of, of sort of corporate strategics, there is so much time wasted on designing a slide that looks right, moving around boxes, changing colors, and you...
There's so much lost in, in that sort of work that could be otherwise applied to, like, the actual thinking that goes into a really well-crafted document. Maybe it's, maybe it is one or two pages, right? Um, maybe it doesn't have to be 20 pages, but that's part of the effort is, like, it is. Like, there's a lot, there's a lot of work done, really good work done in the actual writing of that sort of artifact, if you will, right? So. Yeah. And what I tell my team, you know, as they get to know me better, you know, over the last two months or so, I tell them, "Look, for me it's one simple rule. Content goes over form." Hmm.
If you come to me and say, "Sorry, here's the write-up. It probably doesn't read beautifully yet, and it's not nicely formatted and crafted, but this is the content, this is what we need to know, this is what we need to do," that is okay. We're gonna get there. You know, we're gonna get to the beautiful document and everything. Mm-hmm. But it cannot be beautiful, to your point of the PowerPoint slide- Hmm... and have not the right content. Hmm. That's not negotiable. Sounds like substance over, uh, over sort of, uh, you know, flavor, if you will, right? Um- Exactly. Yeah. Let, let's get to the next, ne- next, uh, kind of subject I wanted to chat, chat with you around, which is, um, which is largely related to kinda the, um, the, the platform capabilities of, of Panther's technology, right?
Maybe frame this up for other, other CEOs that are kind of, are faced with the same sort of challenge. It's a good challenge, right? Of basically we, we could go in a lot of different directions with this novel technology, but we've gotta start somewhere, and it looks like you're kinda starting out with more cosmetics, medical aesthetics. Walk us through kinda how you're thinking about starting there versus, versus, you know, maybe another, another area, right, of health or, or, or, or medicine. And what, what do you think a company like, like Panther has to, has to get right in terms of preventing itself from, like, k- kind of going too wide and an inch deep, right?
Versus really kind of nailing a, a few key, few key applications first? Well, I think, you know, especially when you build a physical product, I think the right advice is very quickly to do so with a first product and learn along the way so that you, you know, touch the whole supply chain, the whole value chain. Hmm. It is just super easy to sit here and have, you know, hours of discussion between you and I around how we think the product should look like, and make nice graphs and, you know, have a couple of scientists to figure out what could be the next molecule, and we're gonna be very, very happy people.
But when you start to really produce more than, like, 10 a day, 100 a day, 1,000 a day, you're like- Oh, wow. This is hard. This is really hard. And I think that's what we're trying to do. We're trying really to, to earn the right to do more via doing the hard things first. Because what does it help me if I figure out how, you know, I can encapsulate a molecule in a vaccine in 10 years from now if I've never produced more than 20 of these or 100? Hmm. That's not useful.
Then I still have no solution. And I think especially when you bring a new product category or a, you know, a new product format, which that is almost, you will want to see how people use it, how they feel about it, and you only can do that in a, you know, more, more simpler setting. Uh, and cosmetic is one of these simpler settings, right? Hmm. Where you have no FDA, FDA regulation. I mean, we will do clinical studies for sure. Uh, we just have one running right now, so we will be...
you know, have all of that because it's gonna be a very, you know, very premium cosmetic lines, you know, which we develop with, with, uh, the leading derms actually in the US. Hmm. But yeah, it's not, it's not putting a vaccine in your body. Hmm. It's just not the same thing. And so I think that's the right thing. You need to start end-to-end understanding how you do that. And then for our platform, you know, for our user experience, where it's the app and there's a microchip in the, uh, in the smart patch, which is super interesting, which allows you to validate your treatment and to really understand what's going on.
Hmm. Also that, you know, you wanna essentially use these first products to prove and validate your platform on both ends, on the consumer end, but also on the partner end. Got it. Can you touch on the, the chip that's super unique? Like, what, what do you think that, uh... what sort of value does that, does that bring to the, to the na- technology? And may- maybe even use like a, a cosmetic application, right? Since this is, uh, kind of more of a, the near-term focus for the company. [upbeat music] Hey, everyone, let's take a quick break. Quick reminder that while we're cooking up something new for MedSider, all 250-plus interviews and our popular email-based courses are now officially consolidated over at scottnelsonlive.com.
These courses are completely free, self-paced, and delivered directly to your inbox over eight weeks. You'll get actionable insights packed with winning formulas from world-class founders and CEOs covering every key stage of the startup journey, like fundraising, device design and development, clinical and regulatory strategy, commercialization, and M&A. Each course covers hard-earned lessons shared by the medical device and health technology entrepreneurs who've joined our program. You can explore the courses at scottnelsonlive.com/courses. Again, that's scottnelsonlive.com/courses. All right, let's jump back to the interview. You have the, the patch and, you know, you take your phone and you go near the chip, and then the app opens up, right?
And then it tells you exactly where to put the patch and, you know, will scan your face, and it tells you exactly, put it here or here. Then you'll take pictures before and after. And you know, I think the amazing thing is that we're at the time where the technology we have available is really making this right now the right step for Panther. Hmm. Like, five years ago without AI, yeah, sure, I can take a picture from your face, but it's not gonna be as, uh, beneficial as it is today.
You take a picture and it can make the analysis, and it can say, "This is how the patch worked out," right? So this instant validation in a very, very high quality, all of these things are possible right now. And so with that, we're creating actually a, a connection to the consumer nobody has ever built. Hmm. Nobody will know that this is Scott. You know what, we... I don't need to know that it's Scott. Mm-hmm. But I need to know what your skin type is, you know, and I will know probably what your age is and how often you've used it, and that is very, very exciting data to have. No doubt.
And so, so, so pragmatically speaking, if I... let's, let's, let's use like a cosmetic application. You know, say it's for, I don't know, I'm just throwing out- Sure... an idea, right? It's, it's reducing wrinkles. Something as, as, as, as- Right... sort of aesthetic as that. Does this chip sort of e- effectively tell me, like, whether or not the therapy actually worked then? Right. So, okay. Yeah. So kind of going back to your point around, look, some of these collagen peptides can't even, like, penetrate the [laughs] the skin membrane. Is it sort of that level of granularity that the- Yeah... that you'll be able to... Okay. Interesting. Yeah. We'll scan your skin and then, you know, use the patch and perhaps we'll say, "Hey, you should use another patch in three days from now."
Perhaps we'll say, "Well, why don't you wait four days?" Hmm. Right? We will have our regimen where we say, uh, you know, twice a week you should use it. Yeah. But again, not everybody's the same. And when you think about it today, you go to the doctor, right? You have a problem and he will tell you, "Oh, well, take this topical cream and use it two times a day." But perhaps Scott doesn't need two times a day. Hmm. Perhaps you need only one time a day. Perhaps you need three times a day. The problem is you don't know. And so your treatment is actually not that personalized. Hmm. It's based on the doctor's evaluation. Now, if you have the ability to essentially continuously control and validate, that will be actually pretty nice thing to do. Oh, wow.
So not o- not only a better way to deliver the therapy, but a much more personalized [laughs] personalized delivery, uh, as well. So yeah, okay. Super, super interesting tech, and I can see why, why you mention even more important that you, that you nail sort of the end-to-end kind of aspect in one application before moving on, right, to others, which probably speaks to your, your, your thinking kind of on a, on a, on a global scale sort of level, you know, rooted in your experiences at, at, at P&G and Amazon. Let's get to the, to, to kind of the, the clinical work associated with this product, 'cause you said you're running, run- you're running one study now.
How are you thinking about the import- balancing kind of the importance of, of clinical validation against just the need to move fast, right, as a, as a startup? Or, I mean, are you, are you, uh... how are you effectively able to, you know, to manage both? I think, you know, when you really define a couple of ground truth of tenets you're not moving away from, that helps you always to make these decisions actually really easy. And one of the things the founder, Carlos Bola, and I are, have been aligned from the beginning, he's a, he's a absolute super focused, you know, product guy.
And it was- Our product needs to be, have the highest quality of any ingredient available. Hmm. So if we put hyaluronic acid in it, it will come from the best hyaluronic acid producer on this planet, and it has to be the best grade. If we put collagen in, it will have to be the best collagen available. Like, there will be no compromises. This is not gonna be a discount product, you know, for $3.99. This is not what we're interested to build. Hmm. It has to be a top-notch product.
And if that is true, then we absolutely will want to have the clinical proof. And I think these both go together. I think you need to be clear on what you want to build. Hmm. And once you're clear on what you want to build, the decision's almost made for you to a certain extent. Hmm. Yeah, good stuff. On that note, let's, let's, let's dive into kind of this, this topic of kind of partnerships and, and broader collaboration 'cause you certainly did a lot of that work, right, at PHE and then, and then Amazon, of course, right? Um, working with a number of different partners. And it looks like based on kind of, you know, our, our research leading up to this conversation, you're doing some early, early collaboration with pharma and biotech companies.
So when you think about establishing the right type of partnership, right, something that's a win for the other side, but also a win obviously for your- for, for Panther and your company as well, are there a couple key things that you think, you know, other CEOs really need to get right when they're thinking about kind of these, these, these key, uh, these key relationships? Yeah, I think, you know, these things, it's always like you can make it as complex as you want, right? Mm-hmm. In theory. Mm-hmm. You can make a long list of, uh, these are all my, my, you know, the, the characteristics I'm gonna decide on. I'm... On these things, I'll force myself to stay really simple. Simple is very often good.
[laughs] And you know, when I think about the partnerships, and again, s- there's obviously nuances, but my f- first discussion I had also with my team was let's look at this in a very simple grid. So there's complexity and then there's commercial success. Interesting. This is big enough. And somewhere there's a quadrant where there's [laughs] like- Hmm... high complexity, you know, and low commercial TAM or whatever you wanna call it. Mm-hmm. And you're like, "Well, I'm not sure if that's where I wanna start." Hmm. Perhaps you wanna start in the areas which are lower complexity and have a high commercial probability of success. And so that's what we're doing right now.
So, and then commercial success means, well, is that molecule easily brought today via topical, for example? And the answer is yes, then yeah, you can put it in a smart patch, but is that so much better- Hmm... for the consumer? And now I'm going back to the previous one we talked at the beginning. You need to start with the consumer. Like, my first question would be always when they would come, "Well, we should work with this company on that molecule," I'd be like, "Okay, what, what's the benefit versus what people have today?" Hmm. Now, if it's a molecule you can't bring into the skin today, well, that's already a pretty big, good argument, right? Mm-hmm. But it's not really available.
So if you really want collagen in your skin, there is no way to put collagen in your skin right now via cream. Hmm. It's just not biology. It's not my fault. Mm-hmm. You know, perhaps that's a good place to start versus, oh yeah, that molecule X, it's not a big problem. It's a very small one. You can put in a cream and your skin is absorbing it. Perhaps then it's less interesting to use a new technology for it. I think that's how I think about it. I try to be as simple as possible and for sure there are nuances around it, but that's how we generally start. Yeah. It's simple, right? But, um, uh, easy- easier said than, than done, right?
'Cause I think any startup, especially if you're working on a, a platform sort of technology like this, could get easily distracted, right, by something that may- maybe there's a huge need, but to your point, the commercial viability just isn't there, right? Or the market opportunity isn't there or vice versa, right? Like, maybe there's a, a huge market need, but, you know, there's, it's, it's super, uh, the c- the complexity is just too, too daunting, right? Or not worth taking on. Yeah. I mean, what we're working on is, of course, also, you know, when you think about a platform, the power of the platform, that's what I learned at, at Amazon, is coming from a high level of automation. Hmm.
If you have to hire tons and tons and tons of people to grow your platform, something is wrong. Hmm. So we are working super hard also on automating a lot of this work. So how can we, to your point, very quickly evaluate what options we have also on the science side, because now you get this molecule from your partner and you find the right biopolymer to combine it with. There are several options. So now do I need a, a year to figure out which biopolymer would fit to that, or can I do that perhaps with AI in weeks?
And so building out the automation part on every part of the platform is a big focus area of ours. Yeah. 'Cause to your point, otherwise you're gonna be in five years from now like, "Oh, I can do two partners, or I have to hire another 25 people." No, that's probably not the right trade-off. Talk to us a little bit, uh, about this recent, this recent kind of, uh, relationship with Pitt BioForge, right? Maybe explain what, what, what that is. And I'm really curious to get your thought on, as you think about scaling this, you know, from a manufacturing standpoint, there's probably a few things that you either really need to get right or you think need to be in place, right, before you kind of maybe get to the next phase of, of, of manufacturing.
And so would love to kind of, uh, get your, get your insight on, on that topic. Yeah. Pitt BioForge, the, the technology of the, the microneedle patch, it comes from Pittsburgh University. Hmm. Uh, it's kind of born there with a couple of other universities, but they're, they have been the lead. And Ken Gabriel, you know, he's the leader of Pitt BioForge. I mean, he, he's just an amazing human being. You know, he's helped us so much and supported us. He is so experienced. I mean, he was, uh, deputy director of DARPA. He has been CEO of companies. And he has, very early on, helped us to understand how can we think about manufacturing, right? Hmm. Because we immediately said, "This is not just an idea." [laughs] We need to be...
If we wanna do anything with this technology, we have to be able to produce it in the millions and not just, like, in, in a small amount. And he was just a fantastic, um, uh, and still is today, a fantastic advisor, supports us. And so we, we learned a lot from him. You know, as we start scaling that, you know, it's, it's, it's just a little bit like, you know, you crawl before you walk, so- Hmm... you know, a month ago we could only produce, I don't know, you know, five a day or 10 a day. It was very, very manual. And right now we're able to produce, you know, 100, 150 a day- Hmm... in a clean room. You know?
It's like, this is not automated, but I can make enough to do a clinical trial and another clinical trial, and, you know, now we're working against, okay, how is the first manual line looking, looking like? And we're working with a couple of engineering partners to, to work through that. And, uh, we'll have a, very shortly actually, our first, first design. And once we have the manual line, you know, then it's like, okay, how can we automate this more? So we'll take one step after the other, you know? Yeah. And I think that's coming back to what you and I talked at the beginning, that's why I think it's important to have a product also in mind and a launch date. That drives your team very differently. I think,
you know, if you wanna make really progress in a startup, you need to get this inflection point pretty fast where you chuck out product. If it's, you know, software or hardware, it doesn't really matter. Because it, it drives the team differently. Hmm. It drives a different sense of urgency. So true. I, I've seen that firsthand. Yeah. It, it's, um, it's, it's one of those thing- I, I, I know when I experienced it, um, even at, even in the, the startup before this one, where it's like once you get to that, that, that point where actually, you know, the, the product is out in the wild, whether it's in the, in the form of like a, a, a clinical study or like true, like a true commercial launch, it sets a different tone within the, within the company, right?
And, uh, I think, and o- o- often cases that's, that's a good thing, right? 'Cause you know, [laughs] you know who's ready to kinda move on to the, the next, the next phase, uh, uh, of kind of where the company's at. One, one thing that I wanted to touch on too is, like, you know, I was looking at your, the, the, the website and I noticed that, when I was looking at, at, at, at your team, two things. One is, like, a really, really strong group of advisors, right? You mentioned a couple names. Car- Carlos obviously as, as, as the founder, pretty, uh, legendary in his own right. But then, like, Dr. Ling, who was the, um, uh, if I remember correctly, the, like one of the, the foundi- the, the founders of DAR- of DARPA, was like ear- early involvement in DARPA in, in a leadership capacity, et cetera.
How, how do you go about, like, curating this, this level of, of, of kind of a, of a team? And then se- secondarily, I also noticed too that you have this, like, little featured section, right? Of, of like, you know, it's easy for a startup to, like, list the he- like include the headshots of their, of their team. But, like, you go a level further and, like, really highlight kind of like each, each, what each person's, like, their background and et cetera, which I think is, is, is quite unique. And, and so kind of maybe touch on those two as- a- aspects, right? Curation of a really, like, stellar advising team, if you will, and then how you go about, like, really, you know, championing kinda your, your early group of, of, uh, of folks that are really pushing this technology to the next level.
Yeah. I think, you know, there's, um, uh, definitely, you know, a, a huge thank you to Carlos, who was just, like, so capable in this area- Mm-hmm... and so knowledgeable, where that impressed me also from the beginning, you know, he would bring smart money, right? So we've done our seed last year. We're going towards series A now. He's not interested in money. He's interested in smart money, people who can contribute. Hmm. And I love that. And, you know, that makes our investor list a group of people I would spend like two weeks on an island with, and I wouldn't get bored for one minute. Hmm. You know?
Like, like people who, who literally coded iOS with their team 30 years ago- Hmm... would work with Steve. And, you know, very impressive entrepreneurs in their own, to your point, in their own, in their own right. That's number one. And that is fantastic because, you know, we have a saying in the company, which is, "When we don't know what to do or to make a decision, call a friend." Hmm. That's what we say. [laughs] We don't have all the, we don't have all the resources in the world. We have very, very small team, like not even 20 people. And, you know, call a friend. Who do you call? Who is the expert here? And then when you look at our principal advisors, you know, Ken Gabriel we talked about, but, you know, uh, but also Gordon Sanghera. I mean- Hmm... Gordon was the head of, uh, of, of Abbott V R&D, left- Hmm...
and founded Oxford Nanopore, which is like a 5 billion company today- [laughs]... you know, listed at the FTSE in the UK, and he built it up in the last 20 years. And these are people, uh, you know, they're just amazing to work with. And, you know, when I have a, when I have issues on, on manufacturing, I call Gordon. Hmm. I say... Well, I have actually my regular one-on-one with him- [laughs]... because he's so generous with his time. But I think, you know, if I would do this again, and perhaps I will do it again, you know, my, in the next startup, I think the one big learning here is you don't need all of the resources from day one.
Yes, you have to build them, but when you do it right and you can excite people for your cause, you get so much help you would've never thought about. Hmm. Because actually people want to help. Now, they, they need to love the idea and the product and the prospects of it. And on that one we are lucky because, you know, what we're trying to do is, is actually, has really purpose. It's a, it's a really nice mission people can identify themselves with. Hmm. You're, you're touching on something that I think, something that I wished I learned sooner, and I, I certainly, uh, you know, uh, fortunately through mistakes and, and learnings [laughs] I'm able to kind of like, uh, pick up on this now.
But, like, just how, how important it is or how critical it is to make sure that you're, you're establishing relationships with some of those, those stakeholders as early as possible, right? Whether they're an advisor, you know, quote, unquote, "advisor", whether they're an investor that's contributed a lot of, a lot of money, and making sure that you're connecting them as well and kinda creating this, th- this tribe. Sometimes it's easier to just gloss over, right? You, you wanna get to the close a round, close a seed round, right? And kinda move on to the next stage. But so, so important to, right, you know, spend some time to kind of really make the connections there between advisors, investors, et cetera, to help set you up for, you know, either a future fundraise, but in your case even more important, right?
Taking advantage of a lot of those, a lot of those experiences, right? That your, that early team is, is bringing to the table. That's absolutely true. And I think, you know, there's, there's really an interesting factor that, uh, the one is reinforcing the other. It's almost- Hmm... like its own flywheel, right? Yeah. So you have these advisor, and so your investors are like, "Wow, that person's working with you?" Hmm. Well, that drives a lot of confidence 'cause that guy- You know, has done this already five times over and was very successful. Great. For your advisors, the other way around.
So you didn't just collect somewhere some money of somebody who had too much of it. This person is contributing with connections, with insights, with knowledge, so that, that, that also gives, you know, uh, for these advisors, you know, uh, some certain depth. Mm-hmm. And that's what I've seen. And, and by the way, on top, they enjoy each other's company a lot. Yeah. So that, that's the- The bonus, yeah. [laughs] Yeah. That's a, it's a bonus for sure. Yeah. I lo- I love, I love the framework though, like are these... Is this a group of, uh, of people that I can spend an island on, right? Uh, with, and, and not, and not get bored, right?
That's a good, that's a good kind of, uh, perspective or question to ask yourself, right, as you're kinda building out that early, early advisory team. And ideally, uh, ideally again, you're making the connections between kind of advisors, investors, and then, and that, that comm- that early, kinda the early-stage community, if you will. I'm looking at the clock and I realize we're, we're getting short on time. I wanna get to these rapid-fire questions, uh, uh, of the interview. But again, for everyone listening, pantherls.com is the website. We'll link to it in the full writeup. Panther and then ls.com. Uh, really, really interesting technology. Uh, and it's gonna be really fun to kinda see what you guys do, not only just in the near term, right? But I'm super curious kind of where this, where this goes with other, uh, other kind of, uh, other therapeutics as well. So with that said, though, first question on the docket is take us out to end of '27, right?
Is there, is there a kind of a single milestone that you're most, you know, most looking forward to? Yes. We launch our first product. [laughs] Easy. [laughs] Easy. [laughs] And you know, that has a lot of sub-milestones- [laughs]... you know, on, on hiring the right people, you know, standing up, you know, manufacturing, getting our go-to-market done. But, um, yeah, that's what I want my team being laser-sharp focused on. Deliver our launch next year. Yeah. What's the, the billboard message or like the o- the one lesson that you think every entrepreneur really needs to, to, to understand if they're gonna have any sort of, uh, you know, semblance of success in their, their own venture?
I, I don't know if it's one lesson, but I, I would say probably two. The one is really the, the, the extremely strong focus on your customer or consumer, and sometimes there are more than one. So for us as we start, you know, within the derm channel, it's kind of a B2B2C play. So, you know, you wanna have the derms if you wanna be that channel behind you as well. And that's what we've done. We've built up, you know, really actually a top derm, derm board with the best derms in the US, and they tell us, "This is an amazing product." Okay. Well, I start believing it as well now, you know? [laughs] If you really like it, and you have to like it.
So your consumer and your, you know, your partners, I think really listen to them really well is a key, a key success factor because you will never be able to understand sometimes these businesses better than somebody who is doing that since 30-plus years. I can see it's kind of this, this, this maniacal focus on the consumer or the end user. You can see it shine through, right? I mean, obviously you, you witnessed that firsthand in your days at P&G and especially Amazon. I think obviously Amazon's, you know, pretty w- pretty well known for that, that sort of, that sort of culture. But sometimes I just think it's, it sounds so, it sounds so simple and straightforward, but it getting so easily lost, right, in all of the decisions that, you know, a CEO has to make at a startup, right?
But just kinda going back to sort of that ground truth, right, is like, what does the... To your point earlier, I think you... What does the consumer want, right? What, not, not what we think they want. What do they want? Right. Yeah. [laughs] The biggest problem here is actually really when your own intuition. You need to be very, very disciplined. Hmm. Interestingly, you learn that best when you're working on brands or products you have no insight. Hmm. So if you, you know... I remember I, I worked in my past on male shaving when, you know, P&G took over Gillette. Well, you have an opinion. You're a man, right? Mm-hmm. You know exactly how it feels. But when you're on female hygiene at P&G, you have no intuition. Hmm.
That's great because that means you listen much, much more better to what's going on. The problem is that we're naturally as humans, when we talk about products we can use ourselves, have immediate opinion. Hmm. And so this discipline say, "I might have an intuition, I might have an opinion, but I actually should not." Hmm. Like, that is, that is really the hard part. Yeah. We love to involve. [laughs] We love to, right? This is what it is. Yeah. And so that's the one part, and I think the other one is really making sure you're aligned on, on what, what you now call also the ground truth or the tenets.
What is the key things in our company we stand for? And we will not deviate from that. And you know what? When we have to make a decision or trade-off, we go back there. Hmm. And then the decision will be made for us- Yeah... in a, in a good way because, hey, if I do B, I'm violating our first tenet- Hmm... about bringing a top product out with the best, you know, ingredients. So no, I can't do B. Sorry, no option anymore. Now, that might bring you trouble with something else. Yeah. But I think that's really important because it makes the bar very, very high for violating any of these. Hmm.
You can, but the bar is very high. Yeah. And it makes you think very, very deeply about it. Yeah. I, I, I just think it's... I, I wanna just stress this enough. I mean, you, you can't... I mean, you, you can't... You spent so many years, right, in a very execution-oriented, uh, you know, companies. Um, not to say every company is execution-oriented to a certain degree, but like P&G and Amazon, right? It's like, that's like a execution on steroids, and I think that's so healthy 'cause it's, it's easy to say we're, we're gonna be disciplined, right? But this is how you be disciplined, right, is go back to your core tenets, as you mentioned, right? What are we doing with this pro- Is it the most... I think you... W- how did you frame this up earlier?
Like, we are developing therapeutic that we wanna, we wanna deliver is the best. It's gonna be the best, right? [laughs] Absolutely. So if, if something deviates from there, right, then, you know, uh, it, it causes, causes the team to, to pause. I think it's just so healthy 'cause, you know, it's easy to talk about discipline, but another thing to, like, talk about what actually forces discipline, right? It's these sorts of, these sorts of things. Um, all right. Uh, last question I've got for you, uh, Munir, is, um, take us back to your early career. Maybe it's first starting to, you f- first starting to kinda take off, you know, feeling a little bit better about kinda where, where, where things are headed, still learning a lot.
Anything you'd whisper in the, the ears of the, the younger, younger version of yourself? It's a really interesting question. Um, I think the one... I would probably whisper a lot. [laughs] Yeah, yeah. Love to whisper a lot. But if I would have to pick one, I would say keep your focus on the prize. Don't get too confused about the how. Hmm. You know, very often the how you find out along the way, and especially at the beginning, you can't see necessarily. If you ask me now, "Mounir, how do you, how do you exactly gonna do manufacturing? And how are you gonna this? And how are you gonna this?" And I will tell you, "I don't know." Hmm. "I, I, I don't know."
Now, what I do know is that I have a group of very, very smart and talented people who will figure it out. But, you know, you can get scared of the, I don't know exactly the path, but you'll figure out, you know? Mm-hmm. Focus on the end point, on the price, which is deliver a product or launch a product or... And then, you know, work super hard every day to unfold the how. Good way to wrap, wrap, wrap things up. Um, Mounir, I can't thank you enough, uh, for carving out some, some time to do this, uh, this interview. This was, uh, this was a lot of fun, but, uh, very, very cool technology, extremely smart and capable group of people. It'll be fun to kinda watch, uh, watch what, uh, watch what your team, uh, does next.
Yeah, it's great. Uh, thank you so much for the invite. I, I really enjoyed having that discussion. It's great what you do here. I, I love, I love your podcast, so- [laughs]... it's fantastic. Thank you. [laughs] Well, thanks, thanks again for doing it. I'll have you hold on the line. But for everyone listening, again, pantherls.com. We'll link you in the full write-up at pantherls.com. Definitely check out the technology. We'll also link to, uh, Mounir's, uh, LinkedIn profile in the full write-up as well. Uh, thanks for your attention as always. Until the next episode goes live, everyone, uh, take care. [upbeat music] Hey, it's Scott again. One quick thing before you go. You see, I love bringing you insightful conversations with the best founders and CEOs of medical device and health technology startups.
But here's the thing, I'd be super grateful if you could help me reach even more ambitious doers who share our passion. So if you found value in this podcast, if you found yourself nodding your head while listening, or if you simply enjoy what we're doing, please take a moment to leave us a review. It's super easy. Just open the Apple Podcasts app, Spotify, or the podcast app of your choice, search for our show, and scroll down to the ratings and review section. Leave your honest thoughts, and hit that five-star rating if you think we're worthy. Your feedback is incredibly important, and it's the best way to ensure we keep bringing you awesome discussions with leading founders and CEOs. So take a moment to be a good friend and leave that review today.
All right, enough talk about reviews. Stay tuned for another informative episode coming at you soon. [outro music]
In this episode of SNL, we sat down with (https://www.linkedin.com/in/lorne-lucree-mba-3585942/)Lorne Lucree (https://www.linkedin.com/in/lorne-lucree-mba-3585942/), the founder and CEO of...
In this episode of SNL, we sat down with (https://www.linkedin.com/in/brian-le-gette-8956252/)Brian Le Gette (https://www.linkedin.com/in/brian-le-gette-8956252/), co-founder and CEO of (https://ammortal.com/)Ammortal...
In this episode of SNL, we sat down with (https://www.linkedin.com/in/tommoss/)Tom Moss (https://www.linkedin.com/in/tommoss/), co-founder and CEO of (https://signalring.com/)Vital Signals (https://signalring.com/),...
In this episode of SNL, we sat down with Dr. Dustin Freckleton (https://www.linkedin.com/in/dustinfreckleton/), founder and CEO of (https://happysleep.com/)Happy Health (https://happysleep.com/). Happy Health delivers...
In this episode of SNL, we sat down with (https://www.linkedin.com/in/eman-namati/)Eman Namati (https://www.linkedin.com/in/eman-namati/), former President and CEO of (https://www.spectrawave.com/)SpectraWAVE...